Spots Global Cancer Trial Database for car t cell therapy
Every month we try and update this database with for car t cell therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiation Post-CAR T in Refractory Lymphoma | NCT04473937 | Hematologic Mal... Refractory Lymp... | Radiotherapy | 18 Years - | Massachusetts General Hospital | |
| Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | NCT05993949 | Lymphoblastic L... | Dasatinib | 18 Years - | Stanford University | |
| Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) | NCT06285422 | Non Hodgkin's L... Large B-cell Ly... | SC262 | 18 Years - 80 Years | Sana Biotechnology | |
| CAR T Cell Therapy Related Cardiovascular Outcomes | NCT05130489 | Cardiovascular ... B-cell Acute Ly... B-cell Lymphoma... B-cell Lymphoma... Primary Mediast... Diffuse Large B... Cardiotoxicity Cardiovascular ... | 16 Years - | University College London Hospitals | ||
| Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | NCT06285422 | Non Hodgkin's L... Large B-cell Ly... | SC262 | 18 Years - 80 Years | Sana Biotechnology | |
| CAR T Cell Therapy Related Cardiovascular Outcomes | NCT05130489 | Cardiovascular ... B-cell Acute Ly... B-cell Lymphoma... B-cell Lymphoma... Primary Mediast... Diffuse Large B... Cardiotoxicity Cardiovascular ... | 16 Years - | University College London Hospitals | ||
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | NCT04981119 | Solid Tumor, Ad... Colorectal Canc... Non Small Cell ... Pancreatic Canc... CRC NSCLC Pancreas Cancer Mesothelioma Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Mesothelioma, M... Mesothelioma; L... Cancer | Apheresis Next Generation... Long Range NGS ... | 18 Years - | A2 Biotherapeutics Inc. | |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT06121843 | Multiple Myelom... | BMS-986393 Alnuctamab Mezigdomide Iberdomide | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | NCT06297226 | Multiple Myelom... | BMS-986393 | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT06121843 | Multiple Myelom... | BMS-986393 Alnuctamab Mezigdomide Iberdomide | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | NCT05993949 | Lymphoblastic L... | Dasatinib | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
